Breast Cancer Trials

 

• STUDY10485
  
  A Phase 1, Open Label, Dose Escalation and Cohort Expansion First in Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti LAG 3 mAb) Administered Alone or in Combination with REGN2810 (anti PD 1 mAb) in Patients with Advanced Malignancies
  
  To evaluate safety and PK in order to determine an RP2D of REGN3767 as monotherapy and in combination with REGN2810 in patients with advanced malignancies, including lymphoma. To assess preliminary anti-tumor activity of REGN3767 alone and in combination with REGN2810 (separately by cohort) as measured by ORR.
  
  Study Information

  ---

  
  

• STUDY8700
  
  Molecular Analysis for Therapy Choice (MATCH)
  
  This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for whom no standard treatment exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors or lymphomas.
  
  Study Information

  ---

  
  

• STUDY17170
  
  Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
  
  The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
  
  Study Information

  ---

  
  

• STUDY17022
  
  First in Human, Phase 1/1b, Open label, Multicenter Study of Bifunctional EGFR/TGF ß Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients with EGFR Driven Advanced Solid Tumors
  
  The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.
  
  Study Information

  ---

  
  

• STUDY17262
  
  Combination of Autophagy Selective Therapeutics (COAST) in Relapsed Gynecological Cancers, Relapsed Prostate Cancer, or other Advanced Solid Tumors, a Phase I/II Trial
  
  Autophagy is a cancer cell survival mechanism that is involved in cancer growth, treatment resistance, and metastasis. Hydroxychloroquine and nelfinavir mesylate are agents that inhibit the process of autophagy. Metformin, dasatinib, and sirolimus stress autophagy.
  
  Study Information

  ---